Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920777 | 0.83 | MMP2 (0.52) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL16350376 | 0.83 | MMP2 (0.52) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL15221467 | 0.82 | MMP2 (0.51) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29591658 | 0.82 | MMP2 (0.71) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL26661743 | 0.78 | MMP2 (0.55) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL13920584 | 0.78 | MMP2 (0.46) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL13920587 | 0.78 | MMP2 (0.46) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL15221388 | 0.77 | MMP2 (0.45) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL12705546 | 0.76 | FKBP1A (0.36) | FKBP1AMEN1KMT2A | |
| SCHEMBL12705544 | 0.76 | ATM (0.41) | MMP2ANPEPFKBP1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | XDH, UPF1, NOX5 | MMP2 3125/4885ANPEP 3335/4885DPP7 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.